139 results about "Intestinal Microbiome" patented technology

Provided herein, inter alia, are feed or feed additive compositions comprising direct fed microbials (DFMs) and other substances as well as methods for making and using the same for the improvement of a subject's performance and maintenance of a balanced gut microbiome.

The invention discloses a lactobacillus rhamnosus GYX-9 strain and an application of the lactobacillus rhamnosus GYX-9 strain. The lactobacillus rhamnosus GYX-9 disclosed by the invention can be used for regulating the problems of blood lipid metabolism disorder, liver lipid accumulation or pathological injury and the like caused by high-fat diet. The lactobacillus rhamnosus GYX-9 disclosed by the invention can be used for reducing the level of TNF-alpha, increasing the content of IL-10 and regulating colonic immune disorder; the abundance of intestinal microbiome communities is adjusted; according to the invention, the lactobacillus rhamnosus GYX-9 is combined to regulate and control the metabolic disorder caused by high-fat diet on the basis of'intestinal flora-intestine-liver axis'. The normal-temperature viable bacterium fermented milk with the viable bacterium number not less than 108 cfu / mL is also prepared, the normal-temperature viable bacterium fermented milk has remarkable capabilities of lowering cholesterol, combining taurocholate and inhibiting pancreatic lipase, and the pancreatic lipase inhibition rate can reach 67.06%.

Provided herein are compositions, methods, strategies, kits, and articles of manufacture that are useful, inter alia, in the treatment or prevention of diseases or conditions such as those which may be associated with inflammation, infection, allergy, immune dysfunction, or dysbiosis of the intestinal microbiome. In some aspects, the invention provides a synergistic combination of a prebiotics, e.g., a mixture of human milk oligosaccharides, and a probiotic strain, such as a strain capable of internalizing and consuming the rebiotics, e.g., B. longum subsp. infantis.

The invention belongs to the technical field of biology, and particularly relates to animal bifidobacterium subsp. Lactis FMBL B24304AHDM and application thereof.The animal bifidobacterium subsp. Lactis FMBL B24304AHDM is preserved in the China Center for Type Culture Collection on November 18, 2024, the preservation number is CCTCC NO: M 20242505, and the animal bifidobacterium subsp. Lactis FMBL B24304AHDM has the good inhibition capacity on pathogenic bacteria and has the high scavenging capacity on DPPH and ABTS free radicals; the compound has the effect of inhibiting the activity of alpha-glucosidase, alpha-amylase and dipeptidyl peptidase IV, and the oral glucose tolerance and insulin tolerance of T2DM mice can be remarkably reduced; the composition of intestinal microbiome is obviously improved, the abundance and variety of effective microbial communities in the intestinal tract are improved, and the relative abundance of pathogenic bacteria is reduced, so that the disorder of short-chain fatty acids of T2DM mice is improved, and the application prospect is wide.

The invention provides an application of intestinal tract Ticam1 in regulation and control of MASH intestinal tract inflammatory response, the application is characterized in that the Ticam1 in the intestinal tract is inhibited, the growth of Ackermania mucilaginosa is promoted, and the strain code QAA37749.1 is used for catalyzing the conversion of betaine and improving MASH. The invention also provides an application of the intestinal tract Ticam1 in preparation of an MASH drug and a corresponding MASH treatment drug. Research finds that Ticam1 can aggravate intestinal injury of HFD mice, and deletion of Ticam1 in IEC can relieve HFD-induced hepatitis and hepatic fibrosis, improve HFD-induced metabolic disorder and cause change of intestinal microbiome, and further experiment and analysis are combined to obtain an influence mechanism of Ticam1 on MASH, so that a new thought and approach are provided for preparation of MASH treatment drugs, and the application has a broad application prospect. And the method has a remarkable application prospect.

The invention discloses application of lactobacillus rhamnosus to preparation of a product for improving and treating cognitive impairment. The invention discloses the new application of the rhamnosus cheese for the first time, and the rhamnosus cheese can improve or treat cognitive impairment related to aging by improving behavioral function change, brain inflammatory factors, oxidative stress activity and neurotransmitter level caused by aging of mice and regulating transcriptome, intestinal microbiome, metabolome and the like. The lactobacillus rhamnosus has a potential application prospect in the aspect of improving learning and memory ability impairment caused by senescence.

This invention belongs to the field of intestinal microbiome technology, specifically relating to a capsular polysaccharide derived from Bacteroides salorlis CSP6, its preparation method, and its applications. The monosaccharide composition of the capsular polysaccharide is mainly composed of fucose, glucose, and glucosamine, with a molecular weight of 7.139 × 10⁻⁶. 5 The strain described is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M20221993. In vitro studies have found that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can inhibit α-glucosidase; in vivo animal experiments have demonstrated that this capsular polysaccharide can inhibit the rise in postprandial blood glucose and has a hypoglycemic effect.

A prebiotic fiber composition obtained from Gloeoporus thelephoroides, Ganoderma lucidum, Pholiota nameko, and / or Pleurotus pulmonarius; and a method of promoting growth of Anaerostipes sp., Bacteroides uniformis, or both in the gut microbiome of an animal, which method comprises orally administering the prebiotic fiber composition, alone or in further combination with live Anaerostipes sp., Bacteroides uniformis, or both, simultaneously or sequentially.

The invention relates to the technical field of Bian chicken source lactobacillus sharianus, in particular to Bian chicken source lactobacillus sharianus YYBJ-07-01 as well as a preparation method and application of the Bian chicken source lactobacillus sharianus YYBJ-07-01. The Bian chicken source lactobacillus shariensis YYBJ-07-01 is preserved in the China Center for Type Culture Collection on September 23, 2025, the classification name of the Bian chicken source lactobacillus shariensis YYBJ-07-01 is that the Bian chicken source lactobacillus shariensis YYBJ-07-01 is classified and named, and the preservation number of the Bian chicken source lactobacillus shariensis YYBJ-07-01 is CCTCC (China Center for Type Culture Collection) No.M20252093. As a national protection variety, the strong environmental adaptability of Bian chickens is associated with a unique intestinal microbiome. According to the invention, not only is the precious genetic resource of Bian chicken deeply excavated and scientifically utilized, but also a solid material foundation is laid for developing a Bian chicken source lactobacillus sharianus YYBJ-07-01 product, and the application value of a local characteristic variety is improved.

Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.

The present invention relates to an apparatus for providing a companion animal customized service on the basis of intestinal microbiome analysis. The apparatus for providing a companion animal customized service on the basis of intestinal microbiome analysis comprises: an analysis unit for deriving intestinal status information of the companion animal through intestinal microbiome analysis for the companion animal; and a service providing unit for providing a service customized for the companion animal on the basis of the intestinal state information.

The invention provides a risk prediction method and device based on digestive system department diseases, and the method comprises the steps: obtaining clinical data and intestinal microbiome data of a target object, and carrying out the preprocessing and standardization of a clinical data set and the intestinal microbiome data; inputting the preprocessed clinical data into a first encoder to obtain a clinical feature matrix; inputting the preprocessed intestinal microbiome into a second encoder to obtain an intestinal microbiome characteristic matrix; based on a cross-modal attention mechanism, performing bidirectional attention calculation on the clinical feature matrix and the intestinal microbiome feature matrix to obtain fusion features; the method comprises the following steps: performing two-way interaction and fusion on clinical data and microbiome data of a target object, calculating an SHAP value of a fusion feature, taking the fusion feature as an input of a preset risk prediction module, and obtaining a risk prediction value of a disease of the digestive system department, and obtaining the risk prediction value of the disease of the digestive system department through two-way interaction and fusion of the clinical data and the microbiome data of the target object. The method can assist doctors in interpreting which key clinical indexes or intestinal microorganism characteristics have relatively large multi-risk prediction influence, assist clinical decision, and further improve the interpretability of digestive system department disease risk prediction.

Provided herein are pet food compositions and methods. The present invention relates to a pet food composition typically comprising an enteric microbiome component comprising: (i) P-1, 3 / 1, 6-glucan; the weight ratio of (i) (3-1, 3 / 1, 6-glucan to (ii) polyphenol isoflavones of the pet food composition is from about 1: 1 to about 5: 1, and the weight ratio of (i) (3-1, 3 / 1, 6-glucan to (ii) polyphenol isoflavones of the pet food composition is from about 1: 1 to about 5: 1. And wherein the enteric microbiome component is present in an amount effective to produce an increase in the weight ratio of propionate to branched short chain fatty acids in pet faeces and an increase in the weight ratio of short chain fatty acids to branched short chain fatty acids in pet faeces after about 3 days after pet ingestion.

The present invention is directed to an oncolytic vector together with one or more antibiotics, one or more a probiotics or other microbiome-targeting compositions, and / or one or more fecal transplant for use in the treatment of cancer. The invention is also directed to a pharmaceutical composition comprising an oncolytic vector with one or more of the following: an antibiotic, a probiotic, a microbiome-targeting composition and a fecal transplant. The invention is also directed to a kit which comprises a first container, a second container, and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing an oncolytic vector, the second container containing one of the following: an antibiotic, a probiotic, a microbiome-targeting composition or a fecal transplant, and the package insert comprises instructions for treating a subject having cancer using the compositions of the first and second containers, wherein said probiotic, microbiome-targeting composition or fecal transplant comprises or promotes a bacterial species which improves the effect of the treatment with an oncolytic vector in a subject when said bacterial species is present in the gut microbiome of said subject, and wherein said antibiotic is effective against a bacterial species which decreases the effect of the treatment with an oncolytic vector in a subject when said bacterial species is present in the gut microbiome of said subject.

The present drinking therapy is intended to build, promote and maintain the intestinal microbiome (flora balance) and consists of a beverage having at least the following components: a herbal probiotic enzyme beverage (probiotic); necessary prebiotics of vitamins, mineral substances and trace elements are combined; the invention relates to natural nutritional oil rich in omega-3 fatty acid and tocopherol. These ingredients are processed into emulsions, whereby the resulting beverage can be drunk periodically, preferably daily, as part of drinking therapy.

Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising a bacterial consortium that promotes interferon (IFN) response in the gut microbiome of a subject and enhances the anti-tumor effects of certain immune checkpoint inhibitor (ICI) therapies. In some embodiments, the compositions are useful for treating a subject having cancer.

The present invention relates to methods of treating animals with an antimicrobial growth promoter (AGP) to promote a healthy microbiome, the method comprising: a) providing test organisms and a control organism, b) administering a regular regimen of a different AGP to each test organism for about two months, c) collecting DNA from the intestinal content of the test organisms and of the control organism, d) sequencing the DNA of the intestinal contents of the organisms to obtain taxonomic and functional profiles, thereby defining core intestinal microbiomes of the test and control organisms, e) comparing the core intestinal microbiomes of the test organisms and of the control organism, thereby determining which test organism has a healthy microbiome thereby determining which AGP provides the most healthy microbiome, and f) treating the domesticated organism with the AGP which provides the healthy microbiome.

The present invention provides: a composition for diagnosing neurodegenerative diseases comprising an agent capable of detecting a urocanate reductase (UrdA) enzyme, a strain having the enzyme, or a metabolite thereof; and a method for providing information for diagnosing neurodegenerative diseases using the urocanate reductase (UrdA) enzyme, a strain having the enzyme, or a metabolite thereof.

The present invention provides methods for determining the state of a subject's gut microbiome given one or more CAZyme abundances provided from the subject's gut metagenomic data. The present invention also provides methods for maintaining or improving the state of a subject's gut microbiome.

Predicting a weight loss potential from gut microbiome data is described herein. In an example, a system accesses gut microbiome metagenomic sequence data for a subject and determines a measurement of one or more weight loss features from the gut microbiome metagenomic sequence data. The one or more weight loss features define a gut microbiome signature for weight loss response for the subject independent of a body mass index of the subject. The system determines a weight loss potential for the subject based on a comparison of the measurement of the subject to a plurality of reference measurements of the one or more weight loss features for a reference population showing variable weight loss responses. The system outputs the weight loss potential for the subject.

The invention discloses oral multi-drug delivery hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the delivery hydrogel, spirulina platensis and traditional Chinese medicine ingredient astragalus polysaccharide are used as raw materials and are added into network-shaped hydrogel formed by combining carboxymethyl chitosan / sodium alginate. The method is easy to implement, safe in component and high in encapsulation efficiency. The composite hydrogel is stated to have the following effects: after oral administration, the medicine can be protected to completely pass through the stomach, the intestinal retention is prolonged, and the medicine can be continuously released at the focus part; the immune checkpoint inhibitor related intestinal inflammation is relieved, and the anti-tumor effect of the immune checkpoint inhibitor is assisted; and noninvasive monitoring of the medicine in the body is realized. According to the invention, a bioactive material is used as a potential treatment strategy for enhancing anti-tumor reaction and relieving immune checkpoint inhibitor-related adverse reaction, and can be more widely applied to treatment of pathological changes related to intestinal microbiome imbalance.

Provided are a method for predicting a treatment response to cancer immunotherapy, the method comprising a step of evaluating, from feces isolated from a patient, the enrichment of a strain of the order TANB77 according to GTDB phylogenetic classification or taxa belonging to the order TANB77, and a step of predicting a treatment response of the patient to cancer immunotherapy on the basis of the enrichment of the order TANB77 or the taxa; a probiotics composition for improving a treatment response; a fecal microbiota transplantation composition; and a method for screening for candidate prebiotics by using same.

The invention belongs to the technical field of biology, and discloses a biomarker for diagnosing unexplained infertility and application of the biomarker. The invention discloses application of a substance for detecting a biomarker in preparation of a product for diagnosing infertility. According to the invention, intestinal microbiome sequencing, multi-dimensional metabonomics (serum / tissue targeting-non-targeting analysis) and high-precision immune cell factor maps are integrated for the first time; the level of amino acid intestinal flora secondary metabolites (such as cinnamic acid, benzoic acid, aspartic acid, lysine, arginine, glutamine, histidine and the like) in plasma of an unexplained infertility patient is remarkably reduced, and part of the metabolites (such as cinnamic acid) have anti-inflammatory immune regulation activity. The plasma amino acid intestinal flora secondary metabolite can be used as a noninvasive biomarker for diagnosing infertility caused by unknown reasons.

The invention discloses a gastrointestinal delivery carrier of a high-activity rhodotorula compound and application of the gastrointestinal delivery carrier in colon fermentation, and belongs to the field of research of food science, pharmaceutical preparations, nutriology and microbiology. The invention explores the storage stability and digestive tract metabolism conditions of the rhodotorula high-activity compound under different carrier forms, namely corn oil (F-oil) loaded with the rhodotorula high-activity compound, corn oil nano-emulsion spray drying powder (F-EP) of the rhodotorula high-activity compound and corn oil nano-emulsion alginate gel (F-EPA) of the rhodotorula high-activity compound. Wherein the storage stability of the F-EPA is optimal. The three carriers do not release the high-activity rhodotorula compound in the in-vitro oral cavity and stomach stages, but in the small intestine stage, the digestibility and the biological accessibility of F-EP are the highest, and the release of F-EPA is the minimum. The F-EPA can effectively promote the rhodotorula red pigment to regulate the structural composition and abundance value of intestinal microbiome.

The invention discloses an application of a flammulina velutipes extract in preparation of related products for relieving and / or treating drug-induced liver injury. By constructing a drug-induced liver injury model, it is found that by means of the needle mushroom extract rich in needle mushroom polysaccharide in low dosage, liver pathological injuries such as cisplatin-induced hepatocyte swelling and necrosis can be remarkably relieved, the levels of serum liver function indexes of alanine transaminase and aspartate transaminase are reduced, and the liver injury resistance is improved. And meanwhile, the activity of superoxide dismutase and glutathione peroxidase in liver tissues is improved, the concentration of malonaldehyde is reduced, and excellent antioxidant characteristics are shown. In addition, the invention also discovers that the flammulina velutipes extract can improve the composition of intestinal microorganisms, promote colonization of beneficial bacteria, reduce the abundance of harmful bacteria and regulate the key metabolic pathway of the liver at the same time, and can provide a treatment strategy for the treatment of drug-induced liver injury.

Powder compositions comprising one or more therapeutic ingredients including fiber and processes of manufacturing the same. Such compositions can be used as a prebiotic dietary supplement to maintain and / or improve the gut microbiome and overall gut health of a human.

The present invention belongs to the technical field of biomedicine, and discloses the application of an intestinal microbiota combination in the preparation of a medicament for treating Systemic lupus erythematosus (SLE). The intestinal microbiota combination of the present invention comprises Ligilactobacillus murinus and / or Faecalibaculum rodentium. After the intestinal microbiota transplantation of the intestinal microbiota combination in lupus mice, the intestinal inflammatory response of the lupus mice can be improved, and the expression levels of autoantibodies and inflammatory factors can be effectively reduced, significantly improving the disease progression of the lupus mice, providing a new idea and method for the treatment of SLE diseases.

This document relates to methods and materials involved in assessing and / or treating a mammal having cancer (e.g., lymphoma). For example, methods and materials that can be used to determine if a mammal (e.g., a human) having cancer (e.g., lymphoma) is likely to respond to or has a cancer or a gut microbiome that makes that mammal more responsive to a particular cancer treatment are provided. Methods and materials for treating a mammal having cancer (e.g., lymphoma) are also provided.

The invention relates to a composition for preventing and treating alcoholic liver injury and application thereof. The composition mainly comprises the following active ingredients: wheat peptide, soft-shelled turtle peptide and kudzuvine root powder. According to the invention, zebra fish is used as a model organism, ethanol exposure treatment is utilized to induce and establish an alcoholic liver injury model, and the alcoholic liver injury is identified by means of apparent histomorphology observation, biochemical index detection, gene expression quantity analysis and the like. Two bioactive peptides (wheat peptides and soft-shelled turtle peptides) screened from six bioactive peptides and five plant extracts are compounded with one plant extract (radix puerariae powder), and the effects of dispelling the effects of alcohol and protecting the liver of the compound are explored from the aspects of enteric microbiomics and non-targeted metabonomics. Researches show that the intervention of the compound significantly improves the hepatomegaly induced by alcohol, and has a synergistic effect in the aspects of preventing hepatocyte injury (improving ALDH activity) and oxidative injury (improving SOD activity) caused by alcohol.